Altria Just Sued the FDA. Here’s What It Means for Your Dividend Check
Key TakeawaysPost-Earnings Reversal: Altria’s Q2 adjusted EPS of $1. 48 missed consensus by two cents and sent shares down as much as 9% to $68, their worst single day since June 2022, even as management raised the low end of full-year guidance to $5.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo